ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Clyde DF, 1975. Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. Am J Trop Med Hyg 24: 397–401.
-
2.
Clyde DF, 1990. Immunity to falciparum and vivax malaria induced by irradiated sporozoites: a review of the University of Maryland studies, 1971–75. Bull World Health Organ 68 (Suppl):9–12.
-
3.
Hoffman SL, Goh LM, Luke TC, Schneider I, Le TP, Doolan DL, Sacci J, de la Vega P, Dowler M, Paul C, Gordon DM, Stoute JA, Church LW, Sedegah M, Heppner DG, Ballou WR, Richie TL, 2002. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis 185: 1155–1164.
-
4.
Rieckmann KH, 1990. Human immunization with attenuated sporozoites. Bull World Health Organ 68 (Suppl): 13–16.
-
5.
Nussenzweig RS, Vanderberg J, Most H, Orton C, 1967. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. Nature 216: 160–162.
-
6.
Gwadz RW, Cochrane AH, Nussenzweig V, Nussenzweig RS, 1979. Preliminary studies on vaccination of rhesus monkeys with irradiated sporozoites of Plasmodium knowlesi and characterization of surface antigens of these parasites. Bull World Health Organ 57 (Suppl 1): 165–173.
-
7.
Collins WE, Skinner JC, Millet P, Broderson JR, Filipski VK, Morris CL, Wilkins PP, Campbell GH, Stanfill PS, Richardson BB, Sullivan J, 1992. Reinforcement of immunity in Saimiri monkeys following immunization with irradiated sporozoites of Plasmodium vivax. Am J Trop Med Hyg 46: 327–334.
-
8.
Weiss WR, 1990. Host-parasite interactions and immunity to irradiated sporozoites. Immunol Lett 25: 39–42.
-
9.
Nussenzweig R, Vanderberg J, Most H, 1969. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. IV. Dose response, specificity and humoral immunity. Mil Med 134: 1176–1182.
-
10.
Sedegah M, Weiss WW, Hoffman SL, 2007. Cross-protection between attenuated Plasmodium berghei and P. yoelii sporozoites. Parasite Immunol 29: 559–565.
-
11.
Mauduit M, Gruner AC, Tewari R, Depinay N, Kayibanda M, Chavatte JM, Franetich JF, Crisanti A, Mazier D, Snounou G, Renia L, 2009. A role for immune responses against non-CS components in the cross-species protection induced by immunization with irradiated malaria sporozoites. PLoS ONE 4: e7717.
-
12.
Verhave JP, Strickland GT, Jaffe HA, Ahmed A, 1978. Studies on the transfer of protective immunity with lymphoid cells from mice immune to malaria sporozoites. J Immunol 121: 1031–1033.
-
13.
Chen DH, Tigelaar RE, Weinbaum FI, 1977. Immunity to sporozoite-induced malaria infeciton in mice. I. The effect of immunization of T and B cell-deficient mice. J Immunol 118: 1322–1327.
-
14.
Doolan DL, Hoffman SL, 2000. The complexity of protective immunity against liver-stage malaria. J Immunol 165: 1453–1462.
-
15.
Del Giudice G, Grillot D, Renia L, Muller I, Corradin G, Louis JA, Mazier D, Lambert PH, 1990. Peptide-primed CD4+ cells and malaria sporozoites. Immunol Lett 25: 59–63.
-
16.
Egan JE, Hoffman SL, Haynes JD, Sadoff JC, Schneider I, Grau GE, Hollingdale MR, Ballou WR, Gordon DM, 1993. Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites. Am J Trop Med Hyg 49: 166–173.
-
17.
Schofield L, Ferreira A, Altszuler R, Nussenzweig V, Nussenzweig RS, 1987. Interferon-gamma inhibits the intrahepatocytic development of malaria parasites in vitro. J Immunol 139: 2020–2025.
-
18.
Seguin MC, Klotz FW, Schneider I, Weir JP, Goodbary M, Slayter M, Raney JJ, Aniagolu JU, Green SJ, 1994. Induction of nitric oxide synthase protects against malaria in mice exposed to irradiated Plasmodium berghei infected mosquitoes: involvement of interferon gamma and CD8+ T cells. J Exp Med 180: 353–358.
-
19.
Overstreet MG, Cockburn IA, Chen YC, Zavala F, 2008. Protective CD8 T cells against Plasmodium liver stages: immunobiology of an ‘unnatural’ immune response. Immunol Rev 225: 272–283.
-
20.
Romero JF, Ibrahim GH, Renggli J, Himmelrich H, Graber P, Corradin G, 2007. IL-12p40-independent induction of protective immunity upon multiple Plasmodium berghei irradiated sporozoite immunizations. Parasite Immunol 29: 541–548.
-
21.
Leiriao P, Mota MM, Rodriguez A, 2005. Apoptotic Plasmodium-infected hepatocytes provide antigens to liver dendritic cells. J Infect Dis 191: 1576–1581.
-
22.
Weiss WR, Sedegah M, Beaudoin RL, Miller LH, Good MF, 1988. CD8+ T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites. Proc Natl Acad Sci USA 85: 573–576.
-
23.
Doolan DL, Hoffman SL, 1999. IL-12 and NK cells are required for antigen-specific adaptive immunity against malaria initiated by CD8+ T cells in the Plasmodium yoelii model. J Immunol 163: 884–892.
-
24.
Herrington D, Davis J, Nardin E, Beier M, Cortese J, Eddy H, Losonsky G, Hollingdale M, Sztein M, Levine M, Nussenzweig RS, Clyde D, Edelman R, 1991. Successful immunization of humans with irradiated malaria sporozoites: humoral and cellular responses of the protected individuals. Am J Trop Med Hyg 45: 539–547.
-
25.
Hurtado S, Salas ML, Romero JF, Zapata JC, Ortiz H, Arévalo-Herrera M, Herrera S, 1997. Regular production of infective sporozoites of Plasmodium falciparum and P. vivax in laboratory-bred Anopheles albimanus. Ann Trop Med Parasitol 91: 49–60.
-
26.
Herrera S, Perlaza BL, Bonelo A, Arevalo-Herrera M, 2002. Aotus monkeys: their great value for anti-malaria vaccines and drug testing. Int J Parasitol 32: 1625–1635.
-
27.
Jordan-Villegas A, Zapata JC, Perdomo AB, Quintero GE, Solarte Y, Arevalo-Herrera M, Herrera S, 2005. Aotus lemurinus griseimembra monkeys: a suitable model for Plasmodium vivax sporozoite infection. Am J Trop Med Hyg 73: 10–15.
-
28.
Arevalo-Herrera M, Castellanos A, Yazdani SS, Shakri AR, Chitnis CE, Dominik R, Herrera S, 2005. Immunogenicity and protective efficacy of recombinant vaccine based on the receptor-binding domain of the Plasmodium vivax Duffy binding protein in Aotus monkeys. Am J Trop Med Hyg 73: 25–31.
-
29.
Arnot DE, Barnwell JW, Tam JP, Nussenzweig V, Nussenzweig RS, Enea V, 1985. Circumsporozoite protein of Plasmodium vivax: gene cloning and characterization of the immunodominant epitope. Science 230: 815–818.
-
30.
Atherton E, Logan CJ, Sheppard RC-J, 1981. Peptide synthesis. II. Procedures for solid-phase synthesis of substance P and of acyl-carrier protein. Chem. Soc Perkin Trans 1: 538–546.
-
31.
Clyde DF, McCarthy VC, Miller RM, Hornick RB, 1973. Specificity of protection of man immunized against sporozoite-induced falciparum malaria. Am J Med Sci 266: 398–403.
-
32.
Arevalo-Herrera M, Roggero MA, Gonzalez JM, Vergara J, Corradin G, Lopez JA, Herrera S, 1998. Mapping and comparison of the B-cell epitopes recognized on the Plasmodium vivax circumsporozoite protein by immune Colombians and immunized Aotus monkeys. Ann Trop Med Parasitol 92: 539–551.
-
33.
Ndao M, Bandyayera E, Kokoskin E, Gyorkos TW, MacLean JD, Ward BJ, 2004. Comparison of blood smear, antigen detection, and nested-PCR methods for screening refugees from regions where malaria is endemic after a malaria outbreak in Quebec, Canada. J Clin Microbiol 42: 2694–2700.
-
34.
Snounou G, Viriyakosol S, Zhu XP, Jarra W, Pinheiro L, do Rosario VE, Thaithong S, Brown KN, 1993. High sensitivity of detection of human malaria parasites by the use of nested polymerase chain reaction. Mol Biochem Parasitol 61: 315–320.
-
35.
Herrera S, Bonelo A, Perlaza BL, Valencia AZ, Cifuentes C, Hurtado S, Quintero G, Lopez JA, Corradin G, Arevalo-Herrera M, 2004. Use of long synthetic peptides to study the antigenicity and immunogenicity of the Plasmodium vivax circumsporozoite protein. Int J Parasitol 34: 1535–1546.
-
36.
Szarfman A, Lyon JA, Walliker D, Quakyi I, Howard RJ, Sun S, Ballou WR, Esser K, London WT, Wirtz RA, Carter R, 1988. Mature liver stages of cloned Plasmodium falciparum share epitopes with proteins from sporozoites and asexual blood stages. Parasite Immunol 10: 339–351.
-
37.
Galey B, Druilhe P, Ploton I, Desgranges C, Asavanich A, Harinasuta T, Marchand C, Brahimi K, Charoenvit Y, Paul C, Young J, Gross M, Beaudoin RL, 1990. Evidence for diversity of Plasmodium falciparum sporozoite surface antigens derived from analysis of antibodies elicited in humans. Infect Immun 58: 2995–3001.
-
38.
Donovan MJ, Messmore AS, Scrafford DA, Sacks DL, Kamhawi S, McDowell MA, 2007. Uninfected mosquito bites confer protection against infection with malaria parasites. Infect Immun 75: 2523–2530.
-
39.
Bergmann ES, Ballou RW, Krzych U, 1997. Detection of CD4+CD45RO+ T lymphocytes producing IL-4 in response to antigens on Plasmodium falciparum erythrocytes: an in vitro correlate of protective immunity induced with attenuated Plasmodium falciparum sporozoites. Cell Immunol 180: 143–152.
-
40.
Collins WE, Sullivan JS, Morris CL, Galland GG, Richardson BB, 1996. Observations on the biological nature of Plasmodium vivax sporozoites. J Parasitol 82: 216–219.
-
41.
Shute PG, Lupascu G, Branzei P, Maryon M, Constantinescu P, Bruce-Chwatt LJ, Draper CC, Killick-Kendrick R, Garnham PC, 1976. A strain of Plasmodium vivax characterized by prolonged incubation: the effect of numbers of sporozoites on the length of the prepatent period. Trans R Soc Trop Med Hyg 70: 474–481.
-
42.
Luke TC, Hoffman SL, 2003. Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine. J Exp Biol 206: 3803–3808.
-
43.
Hoffman SL, Billingsley PF, James E, Richman A, Loyevsky M, Li T, Chakravarty S, Gunasekera A, Chattopadhyay R, Li M, Stafford R, Ahumada A, Epstein JE, Sedegah M, Reyes S, Richie TL, Lyke KE, Edelman R, Laurens MB, Plowe CV, Sim BK, 2010. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum Vaccine 6: 97–106.
-
44.
Mueller AK, Labaied M, Kappe SH, Matuschewski K, 2005. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature 433: 164–167.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 502 | 448 | 35 |
| Full Text Views | 342 | 11 | 1 |
| PDF Downloads | 102 | 11 | 2 |
Immune Responses and Protection of Aotus Monkeys Immunized with Irradiated Plasmodium vivax Sporozoites
Alejandro Jordán-Villegas
Alejandro Jordán-Villegas
Instituto de Inmunología, Universidad del Valle, Cali, Colombia; Malaria Vaccine and Drug Development Center, Cali, Colombia; Hospital Universitario del Valle, Cali, Colombia; Universidad Nacional de Colombia, Palmira, Colombia; Naval Medical Research Center, U.S. Military Malaria Vaccine Program, Silver Spring, Maryland; Sanaria Inc., Rockville, Maryland
Search for other papers by Alejandro Jordán-Villegas in
Current site
Google Scholar
PubMed
Search for other papers by Alejandro Jordán-Villegas in
Current site
Google Scholar
PubMed
Anilza Bonelo Perdomo
Anilza Bonelo Perdomo
Instituto de Inmunología, Universidad del Valle, Cali, Colombia; Malaria Vaccine and Drug Development Center, Cali, Colombia; Hospital Universitario del Valle, Cali, Colombia; Universidad Nacional de Colombia, Palmira, Colombia; Naval Medical Research Center, U.S. Military Malaria Vaccine Program, Silver Spring, Maryland; Sanaria Inc., Rockville, Maryland
Search for other papers by Anilza Bonelo Perdomo in
Current site
Google Scholar
PubMed
Search for other papers by Anilza Bonelo Perdomo in
Current site
Google Scholar
PubMed
Judith E. Epstein
Judith E. Epstein
Instituto de Inmunología, Universidad del Valle, Cali, Colombia; Malaria Vaccine and Drug Development Center, Cali, Colombia; Hospital Universitario del Valle, Cali, Colombia; Universidad Nacional de Colombia, Palmira, Colombia; Naval Medical Research Center, U.S. Military Malaria Vaccine Program, Silver Spring, Maryland; Sanaria Inc., Rockville, Maryland
Search for other papers by Judith E. Epstein in
Current site
Google Scholar
PubMed
Search for other papers by Judith E. Epstein in
Current site
Google Scholar
PubMed
Jesús López
Jesús López
Instituto de Inmunología, Universidad del Valle, Cali, Colombia; Malaria Vaccine and Drug Development Center, Cali, Colombia; Hospital Universitario del Valle, Cali, Colombia; Universidad Nacional de Colombia, Palmira, Colombia; Naval Medical Research Center, U.S. Military Malaria Vaccine Program, Silver Spring, Maryland; Sanaria Inc., Rockville, Maryland
Search for other papers by Jesús López in
Current site
Google Scholar
PubMed
Search for other papers by Jesús López in
Current site
Google Scholar
PubMed
Alejandro Castellanos
Alejandro Castellanos
Instituto de Inmunología, Universidad del Valle, Cali, Colombia; Malaria Vaccine and Drug Development Center, Cali, Colombia; Hospital Universitario del Valle, Cali, Colombia; Universidad Nacional de Colombia, Palmira, Colombia; Naval Medical Research Center, U.S. Military Malaria Vaccine Program, Silver Spring, Maryland; Sanaria Inc., Rockville, Maryland
Search for other papers by Alejandro Castellanos in
Current site
Google Scholar
PubMed
Search for other papers by Alejandro Castellanos in
Current site
Google Scholar
PubMed
María R. Manzano
María R. Manzano
Instituto de Inmunología, Universidad del Valle, Cali, Colombia; Malaria Vaccine and Drug Development Center, Cali, Colombia; Hospital Universitario del Valle, Cali, Colombia; Universidad Nacional de Colombia, Palmira, Colombia; Naval Medical Research Center, U.S. Military Malaria Vaccine Program, Silver Spring, Maryland; Sanaria Inc., Rockville, Maryland
Search for other papers by María R. Manzano in
Current site
Google Scholar
PubMed
Search for other papers by María R. Manzano in
Current site
Google Scholar
PubMed
Miguel A. Hernández
Miguel A. Hernández
Instituto de Inmunología, Universidad del Valle, Cali, Colombia; Malaria Vaccine and Drug Development Center, Cali, Colombia; Hospital Universitario del Valle, Cali, Colombia; Universidad Nacional de Colombia, Palmira, Colombia; Naval Medical Research Center, U.S. Military Malaria Vaccine Program, Silver Spring, Maryland; Sanaria Inc., Rockville, Maryland
Search for other papers by Miguel A. Hernández in
Current site
Google Scholar
PubMed
Search for other papers by Miguel A. Hernández in
Current site
Google Scholar
PubMed
Liliana Soto
Liliana Soto
Instituto de Inmunología, Universidad del Valle, Cali, Colombia; Malaria Vaccine and Drug Development Center, Cali, Colombia; Hospital Universitario del Valle, Cali, Colombia; Universidad Nacional de Colombia, Palmira, Colombia; Naval Medical Research Center, U.S. Military Malaria Vaccine Program, Silver Spring, Maryland; Sanaria Inc., Rockville, Maryland
Search for other papers by Liliana Soto in
Current site
Google Scholar
PubMed
Search for other papers by Liliana Soto in
Current site
Google Scholar
PubMed
Fabián Méndez
Fabián Méndez
Instituto de Inmunología, Universidad del Valle, Cali, Colombia; Malaria Vaccine and Drug Development Center, Cali, Colombia; Hospital Universitario del Valle, Cali, Colombia; Universidad Nacional de Colombia, Palmira, Colombia; Naval Medical Research Center, U.S. Military Malaria Vaccine Program, Silver Spring, Maryland; Sanaria Inc., Rockville, Maryland
Search for other papers by Fabián Méndez in
Current site
Google Scholar
PubMed
Search for other papers by Fabián Méndez in
Current site
Google Scholar
PubMed
Thomas L. Richie
Thomas L. Richie
Instituto de Inmunología, Universidad del Valle, Cali, Colombia; Malaria Vaccine and Drug Development Center, Cali, Colombia; Hospital Universitario del Valle, Cali, Colombia; Universidad Nacional de Colombia, Palmira, Colombia; Naval Medical Research Center, U.S. Military Malaria Vaccine Program, Silver Spring, Maryland; Sanaria Inc., Rockville, Maryland
Search for other papers by Thomas L. Richie in
Current site
Google Scholar
PubMed
Search for other papers by Thomas L. Richie in
Current site
Google Scholar
PubMed
Stephen L. Hoffman
Stephen L. Hoffman
Instituto de Inmunología, Universidad del Valle, Cali, Colombia; Malaria Vaccine and Drug Development Center, Cali, Colombia; Hospital Universitario del Valle, Cali, Colombia; Universidad Nacional de Colombia, Palmira, Colombia; Naval Medical Research Center, U.S. Military Malaria Vaccine Program, Silver Spring, Maryland; Sanaria Inc., Rockville, Maryland
Search for other papers by Stephen L. Hoffman in
Current site
Google Scholar
PubMed
Search for other papers by Stephen L. Hoffman in
Current site
Google Scholar
PubMed
Myriam Arévalo-Herrera
Myriam Arévalo-Herrera
Instituto de Inmunología, Universidad del Valle, Cali, Colombia; Malaria Vaccine and Drug Development Center, Cali, Colombia; Hospital Universitario del Valle, Cali, Colombia; Universidad Nacional de Colombia, Palmira, Colombia; Naval Medical Research Center, U.S. Military Malaria Vaccine Program, Silver Spring, Maryland; Sanaria Inc., Rockville, Maryland
Search for other papers by Myriam Arévalo-Herrera in
Current site
Google Scholar
PubMed
Search for other papers by Myriam Arévalo-Herrera in
Current site
Google Scholar
PubMed
Sócrates Herrera
Sócrates Herrera
Instituto de Inmunología, Universidad del Valle, Cali, Colombia; Malaria Vaccine and Drug Development Center, Cali, Colombia; Hospital Universitario del Valle, Cali, Colombia; Universidad Nacional de Colombia, Palmira, Colombia; Naval Medical Research Center, U.S. Military Malaria Vaccine Program, Silver Spring, Maryland; Sanaria Inc., Rockville, Maryland
Search for other papers by Sócrates Herrera in
Current site
Google Scholar
PubMed
Search for other papers by Sócrates Herrera in
Current site
Google Scholar
PubMed
A non-human primate model for the induction of protective immunity against the pre-erythrocytic stages of Plasmodium vivax malaria using radiation-attenuated P. vivax sporozoites may help to characterize protective immune mechanisms and identify novel malaria vaccine candidates. Immune responses and protective efficacy induced by vaccination with irradiated P. vivax sporozoites were evaluated in malaria-naive Aotus monkeys. Three groups of six monkeys received two, five, or ten intravenous inoculations, respectively, of 100,000 irradiated P. vivax sporozoites; control groups received either 10 doses of uninfected salivary gland extract or no inoculations. Immunization resulted in the production low levels of antibodies that specifically recognized P. vivax sporozoites and the circumsporozoite protein. Additionally, immunization induced low levels of antigen-specific IFN-γ responses. Intravenous challenge with viable sporozoites resulted in partial protection in a dose-dependent manner. These findings suggest that the Aotus monkey model may be able to play a role in preclinical development of P. vivax pre-erythrocytic stage vaccines.
Author Notes
Financial support: This work was supported by grants from the Special Programme for Research and Training in Tropical Diseases, and by the U.S. National Institute of Allergy and Infectious Diseases (NIAID/TMRC contract no. AI49486-02), the UNDP/World Bank/World Health Organization, and the Instituto Colombiano Francisco José de Caldas para la Ciencia y la Tecnología (COLCIENCIAS).
Disclosure: Judith Epstein and Thomas L. Richie are military service members. This work was prepared as part of their official duties. Title 17 U.S.C. §105 provides that “Copyright protection under this title is not available for any work of the United States Government.” Title 17 U.S.C. §101 defines a U.S. Government work as a work prepared by a military service member or employee of the U.S. Government as part of that person's official duties. The views expressed in this article are those of the author and do not necessarily reflect the views of the U.S. Navy, Department of Defense, or the U.S. Government.
Authors' addresses: Alejandro Jordán-Villegas, Anilza Bonelo Perdomo, Alejandro Castellanos, Miguel A. Hernandez, Liliana Soto, Fabián Méndez, Myriam Arévalo-Herrera, and Sócrates Herrera, Instituto de Inmunología, Edificio de Microbiología, Facultad de Salud, Universidad del Valle and Centro Internacional de Vacunas, Cali, Colombia, E-mails: alejovi@hotmail.com, anbonelo@yahoo.com, alejcaste@yahoo.com, mhernandez@inmuno.org, lsoto@inmuno.org, famendez@univalle.edu.co, marevalo@inmuno.org, and sherrera@inmuno.org. Judith E. Epstein and Thomas L. Richie, Malaria Program, Naval Medical Research Center, U.S. Military Malaria Vaccine Program, Silver Spring, MD, E-mails: Judith.Epstein@med.navy.mil and Thomas.Richie@med.navy.mil. Jesús López, Hospital Universitario del Valle, Cali, Colombia, E-mail: jesus.lopez@hotmail.com. María R. Manzano, Departamento de Ciencias Agrícolas, Universidad Nacional de Colombia, Palmira, Colombia, E-mail: mrmanzanom@palmira.unal.edu.co. Stephen L. Hoffman, Sanaria, Inc., Rockville, MD, E-mail: slhoffman@sanaria.com.
Reprint requests: Sócrates Herrera, Malaria Vaccine and Drug Development Center, Carrera 37 - 2Bis No. 5E - 08, Cali, Colombia, E-mail: sherrera@inmuno.org.
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Clyde DF, 1975. Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. Am J Trop Med Hyg 24: 397–401.
-
2.
Clyde DF, 1990. Immunity to falciparum and vivax malaria induced by irradiated sporozoites: a review of the University of Maryland studies, 1971–75. Bull World Health Organ 68 (Suppl):9–12.
-
3.
Hoffman SL, Goh LM, Luke TC, Schneider I, Le TP, Doolan DL, Sacci J, de la Vega P, Dowler M, Paul C, Gordon DM, Stoute JA, Church LW, Sedegah M, Heppner DG, Ballou WR, Richie TL, 2002. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis 185: 1155–1164.
-
4.
Rieckmann KH, 1990. Human immunization with attenuated sporozoites. Bull World Health Organ 68 (Suppl): 13–16.
-
5.
Nussenzweig RS, Vanderberg J, Most H, Orton C, 1967. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. Nature 216: 160–162.
-
6.
Gwadz RW, Cochrane AH, Nussenzweig V, Nussenzweig RS, 1979. Preliminary studies on vaccination of rhesus monkeys with irradiated sporozoites of Plasmodium knowlesi and characterization of surface antigens of these parasites. Bull World Health Organ 57 (Suppl 1): 165–173.
-
7.
Collins WE, Skinner JC, Millet P, Broderson JR, Filipski VK, Morris CL, Wilkins PP, Campbell GH, Stanfill PS, Richardson BB, Sullivan J, 1992. Reinforcement of immunity in Saimiri monkeys following immunization with irradiated sporozoites of Plasmodium vivax. Am J Trop Med Hyg 46: 327–334.
-
8.
Weiss WR, 1990. Host-parasite interactions and immunity to irradiated sporozoites. Immunol Lett 25: 39–42.
-
9.
Nussenzweig R, Vanderberg J, Most H, 1969. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. IV. Dose response, specificity and humoral immunity. Mil Med 134: 1176–1182.
-
10.
Sedegah M, Weiss WW, Hoffman SL, 2007. Cross-protection between attenuated Plasmodium berghei and P. yoelii sporozoites. Parasite Immunol 29: 559–565.
-
11.
Mauduit M, Gruner AC, Tewari R, Depinay N, Kayibanda M, Chavatte JM, Franetich JF, Crisanti A, Mazier D, Snounou G, Renia L, 2009. A role for immune responses against non-CS components in the cross-species protection induced by immunization with irradiated malaria sporozoites. PLoS ONE 4: e7717.
-
12.
Verhave JP, Strickland GT, Jaffe HA, Ahmed A, 1978. Studies on the transfer of protective immunity with lymphoid cells from mice immune to malaria sporozoites. J Immunol 121: 1031–1033.
-
13.
Chen DH, Tigelaar RE, Weinbaum FI, 1977. Immunity to sporozoite-induced malaria infeciton in mice. I. The effect of immunization of T and B cell-deficient mice. J Immunol 118: 1322–1327.
-
14.
Doolan DL, Hoffman SL, 2000. The complexity of protective immunity against liver-stage malaria. J Immunol 165: 1453–1462.
-
15.
Del Giudice G, Grillot D, Renia L, Muller I, Corradin G, Louis JA, Mazier D, Lambert PH, 1990. Peptide-primed CD4+ cells and malaria sporozoites. Immunol Lett 25: 59–63.
-
16.
Egan JE, Hoffman SL, Haynes JD, Sadoff JC, Schneider I, Grau GE, Hollingdale MR, Ballou WR, Gordon DM, 1993. Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites. Am J Trop Med Hyg 49: 166–173.
-
17.
Schofield L, Ferreira A, Altszuler R, Nussenzweig V, Nussenzweig RS, 1987. Interferon-gamma inhibits the intrahepatocytic development of malaria parasites in vitro. J Immunol 139: 2020–2025.
-
18.
Seguin MC, Klotz FW, Schneider I, Weir JP, Goodbary M, Slayter M, Raney JJ, Aniagolu JU, Green SJ, 1994. Induction of nitric oxide synthase protects against malaria in mice exposed to irradiated Plasmodium berghei infected mosquitoes: involvement of interferon gamma and CD8+ T cells. J Exp Med 180: 353–358.
-
19.
Overstreet MG, Cockburn IA, Chen YC, Zavala F, 2008. Protective CD8 T cells against Plasmodium liver stages: immunobiology of an ‘unnatural’ immune response. Immunol Rev 225: 272–283.
-
20.
Romero JF, Ibrahim GH, Renggli J, Himmelrich H, Graber P, Corradin G, 2007. IL-12p40-independent induction of protective immunity upon multiple Plasmodium berghei irradiated sporozoite immunizations. Parasite Immunol 29: 541–548.
-
21.
Leiriao P, Mota MM, Rodriguez A, 2005. Apoptotic Plasmodium-infected hepatocytes provide antigens to liver dendritic cells. J Infect Dis 191: 1576–1581.
-
22.
Weiss WR, Sedegah M, Beaudoin RL, Miller LH, Good MF, 1988. CD8+ T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites. Proc Natl Acad Sci USA 85: 573–576.
-
23.
Doolan DL, Hoffman SL, 1999. IL-12 and NK cells are required for antigen-specific adaptive immunity against malaria initiated by CD8+ T cells in the Plasmodium yoelii model. J Immunol 163: 884–892.
-
24.
Herrington D, Davis J, Nardin E, Beier M, Cortese J, Eddy H, Losonsky G, Hollingdale M, Sztein M, Levine M, Nussenzweig RS, Clyde D, Edelman R, 1991. Successful immunization of humans with irradiated malaria sporozoites: humoral and cellular responses of the protected individuals. Am J Trop Med Hyg 45: 539–547.
-
25.
Hurtado S, Salas ML, Romero JF, Zapata JC, Ortiz H, Arévalo-Herrera M, Herrera S, 1997. Regular production of infective sporozoites of Plasmodium falciparum and P. vivax in laboratory-bred Anopheles albimanus. Ann Trop Med Parasitol 91: 49–60.
-
26.
Herrera S, Perlaza BL, Bonelo A, Arevalo-Herrera M, 2002. Aotus monkeys: their great value for anti-malaria vaccines and drug testing. Int J Parasitol 32: 1625–1635.
-
27.
Jordan-Villegas A, Zapata JC, Perdomo AB, Quintero GE, Solarte Y, Arevalo-Herrera M, Herrera S, 2005. Aotus lemurinus griseimembra monkeys: a suitable model for Plasmodium vivax sporozoite infection. Am J Trop Med Hyg 73: 10–15.
-
28.
Arevalo-Herrera M, Castellanos A, Yazdani SS, Shakri AR, Chitnis CE, Dominik R, Herrera S, 2005. Immunogenicity and protective efficacy of recombinant vaccine based on the receptor-binding domain of the Plasmodium vivax Duffy binding protein in Aotus monkeys. Am J Trop Med Hyg 73: 25–31.
-
29.
Arnot DE, Barnwell JW, Tam JP, Nussenzweig V, Nussenzweig RS, Enea V, 1985. Circumsporozoite protein of Plasmodium vivax: gene cloning and characterization of the immunodominant epitope. Science 230: 815–818.
-
30.
Atherton E, Logan CJ, Sheppard RC-J, 1981. Peptide synthesis. II. Procedures for solid-phase synthesis of substance P and of acyl-carrier protein. Chem. Soc Perkin Trans 1: 538–546.
-
31.
Clyde DF, McCarthy VC, Miller RM, Hornick RB, 1973. Specificity of protection of man immunized against sporozoite-induced falciparum malaria. Am J Med Sci 266: 398–403.
-
32.
Arevalo-Herrera M, Roggero MA, Gonzalez JM, Vergara J, Corradin G, Lopez JA, Herrera S, 1998. Mapping and comparison of the B-cell epitopes recognized on the Plasmodium vivax circumsporozoite protein by immune Colombians and immunized Aotus monkeys. Ann Trop Med Parasitol 92: 539–551.
-
33.
Ndao M, Bandyayera E, Kokoskin E, Gyorkos TW, MacLean JD, Ward BJ, 2004. Comparison of blood smear, antigen detection, and nested-PCR methods for screening refugees from regions where malaria is endemic after a malaria outbreak in Quebec, Canada. J Clin Microbiol 42: 2694–2700.
-
34.
Snounou G, Viriyakosol S, Zhu XP, Jarra W, Pinheiro L, do Rosario VE, Thaithong S, Brown KN, 1993. High sensitivity of detection of human malaria parasites by the use of nested polymerase chain reaction. Mol Biochem Parasitol 61: 315–320.
-
35.
Herrera S, Bonelo A, Perlaza BL, Valencia AZ, Cifuentes C, Hurtado S, Quintero G, Lopez JA, Corradin G, Arevalo-Herrera M, 2004. Use of long synthetic peptides to study the antigenicity and immunogenicity of the Plasmodium vivax circumsporozoite protein. Int J Parasitol 34: 1535–1546.
-
36.
Szarfman A, Lyon JA, Walliker D, Quakyi I, Howard RJ, Sun S, Ballou WR, Esser K, London WT, Wirtz RA, Carter R, 1988. Mature liver stages of cloned Plasmodium falciparum share epitopes with proteins from sporozoites and asexual blood stages. Parasite Immunol 10: 339–351.
-
37.
Galey B, Druilhe P, Ploton I, Desgranges C, Asavanich A, Harinasuta T, Marchand C, Brahimi K, Charoenvit Y, Paul C, Young J, Gross M, Beaudoin RL, 1990. Evidence for diversity of Plasmodium falciparum sporozoite surface antigens derived from analysis of antibodies elicited in humans. Infect Immun 58: 2995–3001.
-
38.
Donovan MJ, Messmore AS, Scrafford DA, Sacks DL, Kamhawi S, McDowell MA, 2007. Uninfected mosquito bites confer protection against infection with malaria parasites. Infect Immun 75: 2523–2530.
-
39.
Bergmann ES, Ballou RW, Krzych U, 1997. Detection of CD4+CD45RO+ T lymphocytes producing IL-4 in response to antigens on Plasmodium falciparum erythrocytes: an in vitro correlate of protective immunity induced with attenuated Plasmodium falciparum sporozoites. Cell Immunol 180: 143–152.
-
40.
Collins WE, Sullivan JS, Morris CL, Galland GG, Richardson BB, 1996. Observations on the biological nature of Plasmodium vivax sporozoites. J Parasitol 82: 216–219.
-
41.
Shute PG, Lupascu G, Branzei P, Maryon M, Constantinescu P, Bruce-Chwatt LJ, Draper CC, Killick-Kendrick R, Garnham PC, 1976. A strain of Plasmodium vivax characterized by prolonged incubation: the effect of numbers of sporozoites on the length of the prepatent period. Trans R Soc Trop Med Hyg 70: 474–481.
-
42.
Luke TC, Hoffman SL, 2003. Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine. J Exp Biol 206: 3803–3808.
-
43.
Hoffman SL, Billingsley PF, James E, Richman A, Loyevsky M, Li T, Chakravarty S, Gunasekera A, Chattopadhyay R, Li M, Stafford R, Ahumada A, Epstein JE, Sedegah M, Reyes S, Richie TL, Lyke KE, Edelman R, Laurens MB, Plowe CV, Sim BK, 2010. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum Vaccine 6: 97–106.
-
44.
Mueller AK, Labaied M, Kappe SH, Matuschewski K, 2005. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature 433: 164–167.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 502 | 448 | 35 |
| Full Text Views | 342 | 11 | 1 |
| PDF Downloads | 102 | 11 | 2 |